CliffBio
biologic

Sarclisa

isatuximab-irfc

Loss of exclusivityMarch 2032projected — 12-year biologic exclusivity estimate
CompanySanofi-Aventis U.S. LLC

Drug detail

Brand nameSarclisa
Active ingredientisatuximab-irfc
Strength500MG/25ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2020
Marketing statusRx

More from Sanofi-Aventis U.S. LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Sarclisa patent cliff — loss of exclusivity March 2032 | CliffBio